Page 130 - 南京医科大学学报自然科学版

第43卷第4期
·568 · 南 京 医 科 大 学 学 报 2023年4月

vascular atlas reveals diverse mediators of Alzheimer’s Alzheimer disease［J］. JAMA，2023，329（5）：363
risk［J］. Nature，2022，603（7903）：885-892 ［32］ MINTUN M A，LO A C，DUGGAN EVANS C，et al. Don⁃
［20］ COOPER Y A，TEYSSIER N，DRäGER N M，et al. Func⁃ anemab in early Alzheimer’s disease［J］. N Engl J Med，
tional regulatory variants implicate distinct transcriptional 2021，384（18）：1691-1704
networks in dementia［J］. Science，2022，377（6608）： ［33］ ANON.15th conference clinical trials Alzheimer’s dis⁃
8654 ease，November 29 ⁃ December 2，2022，San Francisco，
［21］ HU H，BI Y L，SHEN X N，et al. Application of the amy⁃ CA，USA：symposia ⁃ oral communications ⁃ late breaking
loid/tau/neurodegeneration framework in cognitively in⁃ abstracts（clinical trial Alzheimer’s disease）［J］. J Prev
tact adults：the CABLE study［J］. Ann Neurol，2022，92 Alzheimers Dis，2022，9（Suppl 1）：8-50
（3）：439-450 ［34］ Roche provides update on phase Ⅲ GRADUATE pro⁃
［22］ STRIKWERDA⁃BROWN C，HOBBS D A，GONNEAUD gramme evaluating gantenerumab in early Alzheimer’s
J，et al. Association of elevated amyloid and tau positron disease［EB/OL］.（2022⁃11⁃14）［2023⁃02⁃1］. https：//
emission tomography signal with near⁃term development www.roche.com/investors/updates/inv ⁃ update ⁃ 2022 ⁃ 11 ⁃
of Alzheimer disease symptoms in older adults without 14c
cognitive impairment［J］. JAMA Neurol，2022，79（10）： ［35］ FULLER J P，STAVENHAGEN J B，TEELING J L. New
975-985 roles for Fc receptors in neurodegeneration⁃the impact on
［23］ OSSENKOPPELE R，PICHET BINETTE A，GROOT C，et Immunotherapy for Alzheimer’s disease［J］. Front Neuro⁃
al. Amyloid and tau PET⁃positive cognitively unimpaired sci，2014，8：235
individuals are at high risk for future cognitive decline ［36］ WITHINGTON C G，TURNER R S. Amyloid⁃related ima⁃
［J］. Nat Med，2022，28（11）：2381-2387 ging abnormalities with anti ⁃ amyloid antibodies for the
［24］ MILÀ⁃ALOMÀ M，ASHTON N J，SHEKARI M，et al. treatment of dementia due to Alzheimer’s disease［J］.
Plasma p⁃tau231 and p⁃tau217 as state markers of amyloid⁃ Front Neurol，2022，13：862369
β pathology in preclinical Alzheimer’s disease［J］. Nat ［37］ JUNG H，LEE S Y，LIM S，et al. Anti⁃inflammatory clear⁃
Med，2022，28（9）：1797-1801 ance of amyloid⁃beta by a chimeric Gas6 fusion protein
［25］ ASHTON N J，JANELIDZE S，MATTSSON⁃CARLGREN ［J］. Nat Med，2022，28（9）：1802-1812
N ，et al. Differential roles of A β 42/40，p⁃tau231 and ［38］ TauRx announces results from its LUCIDITY Phase Ⅲ trial
p⁃tau217 for Alzheimer’s trial selection and disease moni⁃ for AD［EB/OL］.（2022⁃10⁃06）［2023⁃02⁃01］. https：//
toring［J］. Nat Med，2022，28（12）：2555-2562 www.alzheimer⁃europe.org/news/taurx⁃announces⁃results⁃
［26］ MIELKE M M，DAGE J L，FRANK R D，et al. Perfor⁃ its⁃lucidity⁃phase⁃iii⁃trial⁃ad
mance of plasma phosphorylated tau 181 and 217 in the ［39］ CUMMINGS J，LEE G，NAHED P，et al. Alzheimer’s dis⁃
community［J］. Nat Med，2022，28（7）：1398-1405 ease drug development pipeline：2022［J］. Alzheimers De⁃
［27］ ALEXANDER G C，KNOPMAN D S，EMERSON S S，et ment（N Y），2022，8（1）：12295
al. Revisiting FDA approval of aducanumab［J］. N Engl J ［40］ WETHERELL J L，HERSHEY T，HICKMAN S，et al.
Med，2021，385（9）：769-771 Mindfulness⁃based stress reduction for older adults with
［28］ TUCKER S，MOLLER C，TEGERSTEDT K，et al. The mu⁃ stress disorders and neurocognitive difficulties：a random⁃
ized controlled trial［J］. J Clin Psychiatry，2017，78（7）：
rine version of BAN2401（mAb158）selectively reduces
amyloid⁃beta protofibrils in brain and cerebrospinal fluid 734-743
of tg⁃ArcSwe mice［J］. J Alzheimers Dis，2015，43（2）： ［41］ GOMEZ⁃PINILLA F，HILLMAN C. The influence of exer⁃
575-588 cise on cognitive abilities［J］. Compr Physiol，2013，3
［29］ SWANSON C J，ZHANG Y，DHADDA S，et al. A random⁃ （1）：403-428
ized，double⁃blind，phase 2b proof⁃of⁃concept clinical tri⁃ ［42］ LENZE E J，VOEGTLE M，MILLER J P，et al. Effects of
mindfulness training and exercise on cognitive function in
al in early Alzheimer’s disease with lecanemab，an anti⁃
Abeta protofibril antibody［J］. Alzheimers Res Ther， older adults：a randomized clinical trial［J］. JAMA，2022，
2021，13（1）：80 328（22）：2218-2229
［43］ IRAM T，KERN F，KAUR A，et al. Young CSF restores
［30］ VAN DYCK C H，SWANSON C J，AISEN P，et al. Lec⁃
anemab in early Alzheimer’s disease［J］. N Engl J Med， oligodendrogenesis and memory in aged mice via FGF17
［J］. Nature，2022，605（7910）：509-515
2023，388（1）：9-21
［31］ LARKIN H D. Lecanemab gains FDA approval for early （下转第576页）